Purchase Order 36C25026P0310

The Department of Veterans Affairs, Veterans Integrated Service Network 10, awarded a $347,000.20 firm fixed-price purchase order to Sofie CO. (doing business as IBA Molecular) on January 20, 2026, for pet radiopharmaceutical services supporting the Nuclear Medicine Service at the Kent Community-Based Outpatient Clinic in Kent, Ohio. The contract, which carries no set-aside designation, has an ultimate completion date of January 19, 2027, and will be performed in Sterling, Virginia. This procurement responds to RFQ 36C25026Q0202, issued under Product Service Code 6505 for drugs and biologicals, and represents a continuation of the VA's ongoing relationship with Sofie CO. as a specialized supplier of positron emission tomography imaging agents.

Sofie CO. is a for-profit subsidiary of Sofie Biosciences, Inc., headquartered in Sterling, Virginia, and specializes in the development, production, and delivery of molecular diagnostics and therapeutic radiopharmaceuticals. The company holds an extensive portfolio of federal contracts with multiple VA Veterans Integrated Service Networks and the Defense Health Agency, supplying critical PET radiopharmaceuticals including PYLARIFY for prostate cancer detection, NEURACEQ for Alzheimer's disease imaging, and fluorodeoxyglucose for general oncology imaging. This purchase order leverages Sofie CO.'s established competitive position and regulatory compliance with U.S. Nuclear Regulatory Commission and Food and Drug Administration requirements to provide essential diagnostic imaging capabilities to veterans through the VA healthcare system.